Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 3/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18770212 | 0.82 | ALDH1A1 (0.43) | POLBALDH1A1SMN1; SMN2LMNAHTR6 | |
| SCHEMBL4867769 | 0.81 | KDM4E (0.44) | POLBALDH1A1SMN1; SMN2CA2CA1 | |
| SCHEMBL4869134 | 0.78 | CA2 (0.56) | ALDH1A1CA2LMNAF2PRSS1 | |
| SCHEMBL2854064 | 0.76 | ALDH1A1 (0.59) | POLBALDH1A1SMN1; SMN2CA2LMNA | |
| SCHEMBL14074428 | 0.75 | BRD4 (0.38) | POLBALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL12325142 | 0.74 | F2 (0.58) | POLBALDH1A1SMN1; SMN2CA2LMNA | |
| SCHEMBL4873352 | 0.74 | KMT2A (0.47) | POLBALDH1A1SMN1; SMN2LMNACYP19A1 | |
| SCHEMBL22916894 | 0.73 | LMNA (0.63) | POLBALDH1A1SMN1; SMN2CA2LMNA | |
| SCHEMBL4872482 | 0.73 | MMP1 (0.51) | ALDH1A1SMN1; SMN2CA2LMNACA1 | |
| SCHEMBL4873295 | 0.72 | ALDH1A1 (0.50) | POLBALDH1A1SMN1; SMN2CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| EP-1086076-B1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | HALE MICHAEL ROBIN (US) | 2004-05-20 | — | — | US | disclosed |
| US-6613743-B2 | Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-04-25 | — | — | US | disclosed |
| EP-1086076-A1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065870-A2 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | POLB 1762/4885ALDH1A1 1841/4885SMN1; SMN2 2199/4885 |
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | POLB 1762/4885ALDH1A1 1841/4885SMN1; SMN2 2199/4885 |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | POLB 1762/4885ALDH1A1 1841/4885SMN1; SMN2 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.